INT199409

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2005
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 2.54
Pain Relevance 0.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A4) oxidoreductase activity (CYP3A4) endoplasmic reticulum (CYP3A4)
enzyme binding (CYP3A4) lipid metabolic process (CYP3A4) cytoplasm (CYP3A4)
Anatomy Link Frequency
plasma 4
CYP3A4 (Homo sapiens)
Pain Link Frequency Relevance Heat
sSRI 1 95.48 Very High Very High Very High
Calcium channel 3 93.00 High High
antidepressant 1 92.00 High High
dexamethasone 27 87.52 High High
Bioavailability 9 65.92 Quite High
antagonist 20 59.36 Quite High
abdominal pain 6 58.80 Quite High
agonist 2 52.56 Quite High
endometriosis 1 46.88 Quite Low
Versed 7 40.76 Quite Low
Disease Link Frequency Relevance Heat
Muscle Disease 11 95.20 Very High Very High Very High
Vomiting 103 93.56 High High
Toxicity 25 93.40 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 70 93.36 High High
Rhabdomyolysis 10 91.24 High High
Myocardial Infarction 6 88.12 High High
Hantavirus Infection 4 81.32 Quite High
Gastric Motility Disorder 35 78.08 Quite High
Arrhythmia Under Development 6 76.28 Quite High
Abdominal Pain 6 58.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Identification of drugs causing irreversible CYP3A4 inhibition
Positive_regulation (causing) of Negative_regulation (inhibition) of CYP3A4
1) Confidence 0.50 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.09 Pain Relevance 0
Drugs such as rifampicin and St John’s Wort, strong CYP3A4 inducers, reduce the concentration of aprepitant/fosaprepitant whereas a strong CYP3A4 inhibitor like ketoconazole can increase the AUC of aprepitant five-fold.
Positive_regulation (increase) of Negative_regulation (inhibitor) of CYP3A4
2) Confidence 0.31 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504061 Disease Relevance 0.33 Pain Relevance 0.12
Etravirine is an inducer of CYP3A4, a weak inhibitor of CYP2C9 and a moderate inhibitor of CYP2C19.
Positive_regulation (inducer) of Negative_regulation (inhibitor) of CYP3A4
3) Confidence 0.20 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2817788 Disease Relevance 0.14 Pain Relevance 0
Etravirine is an inducer of CYP3A4, a weak inhibitor of CYP2C9 and a moderate inhibitor of CYP2C19.
Positive_regulation (inducer) of Negative_regulation (inhibitor) of CYP3A4
4) Confidence 0.20 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2817788 Disease Relevance 0.14 Pain Relevance 0
Inhibitors of CYP3A4 shown to increase serum simvastatin levels include itraconazole, fluconazole, erythromycin, clarithromycin, cyclosporine, danazol, diltiazem, verapamil, amiodarone, grapefruit juice, HIV protease inhibitors, and some antidepressants.
Positive_regulation (increase) of Negative_regulation (Inhibitors) of CYP3A4 associated with antidepressant and acquired immune deficiency syndrome or hiv infection
5) Confidence 0.15 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672455 Disease Relevance 1.09 Pain Relevance 0.08
The proposed mechanism of these drugs is that the plasma level of ERY, a known substrate of CYP3A isozymes, is increased significantly upon CYP3A inhibition, resulting in an increased risk of serious cardiac arrhythmias.
Positive_regulation (increased) of Negative_regulation (inhibition) of CYP3A in plasma
6) Confidence 0.06 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978393 Disease Relevance 0.76 Pain Relevance 0.18
Concomitant administration of DNG and CYP3A4 inducers may result in elevated DNG clearance rates.3 Concurrent treatments with CYP3A4 inhibitors may elevate plasma DNG concentration.3
Spec (may) Positive_regulation (elevate) of Negative_regulation (inhibitors) of CYP3A4 in plasma
7) Confidence 0.06 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2990895 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox